REI to Provide Low-Code Solutions for FDA Workflows

REI Systems has been awarded a $140 million blanket purchase agreement to develop low-code solutions for the Food and Drug Administration.

The five-year award will support workflow management programs used by the FDA’s Center for Drug Evaluation and Research, REI said Monday.

CDER is tasked with regulating over-the-counter and prescription drugs, including biological therapeutics and generic drugs. The center also regulates non-medical products like fluoride toothpaste and antiperspirants.

Under the terms of the new BPA, REI will help CDER streamline, standardize and digitize its drug review and approval process, fast-tracking the path to commercialization.

Megan Hicks, REI’s FDA account director, said the coronavirus pandemic highlighted a need for technology-driven solutions for improving the agency’s drug review and approval process.

“We are thrilled to help streamline, standardize, and automate those processes to get critical drugs to market faster and provide transparency to the public,” Hicks said.

REI said it was selected for its track record of using Agile software development and DevSecOps methodologies in support of FDA projects, as well as its ability to deliver Appian and Salesforce low-code solutions.

In software development, a low-code platform is an environment that allows the user to create applications through a graphical interface instead of hand-coded computer programming.

Kumar Anupam, vice president of REI’s health systems business, said the award demonstrates his division’s competence in implementing health information technology.

REI is an IT company that specializes in application modernization, cloud technology, data management and data analytics.

The company serves health care, national security, science and technology customers in the federal, state, local and nonprofit sectors.